Pharmacokinetic–Pharmacodynamic Modelling: History and Perspectives

A major goal in clinical pharmacology is the quantitative prediction of drug effects. The field of pharmacokinetic–pharmacodynamic (PK/PD) modelling has made many advances from the basic concept of the dose–response relationship to extended mechanism-based models. The purpose of this article is to review, from a historical perspective, the progression of the modelling of the concentration–response relationship from the first classic models developed in the mid-1960s to some of the more sophisticated current approaches. The emphasis is on general models describing key PD relationships, such as: simple models relating drug dose or concentration in plasma to effect, biophase distribution models and in particular effect compartment models, models for indirect mechanism of action that involve primarily the modulation of endogenous factors, models for cell trafficking and transduction systems. We show the evolution of tolerance and time-variant models, non- and semi-parametric models, and briefly discuss population PK/PD modelling, together with some example of more recent and complex pharmacodynamic models for control system and nonlinear HIV-1 dynamics. We also discuss some future possible directions for PK/PD modelling, report equations for general classes of novel semi-parametric models, as well as describing two new classes, additive or set-point, of regulatory, additive feedback models in their direct and indirect action variants

[1]  R A Meiss,et al.  Nonlinear force response of active smooth muscle subjected to small stretches. , 1984, The American journal of physiology.

[2]  M. Danhof,et al.  The Impact of Arteriovenous Concentration Differences on Pharmacodynamic Parameter Estimates , 1997, Journal of Pharmacokinetics and Biopharmaceutics.

[3]  M Davidian,et al.  Population pharmacokinetic/pharmacodynamic methodology and applications: a bibliography. , 1994, Biometrics.

[4]  Steven L. Shafer,et al.  Algorithms to rapidly achieve and maintain stable drug concentrations at the site of drug effect with a computer-controlled infusion pump , 1992, Journal of Pharmacokinetics and Biopharmaceutics.

[5]  L B Sheiner,et al.  Semiparametric approach to pharmacokinetic-pharmacodynamic data. , 1989, The American journal of physiology.

[6]  L B Sheiner,et al.  Pharmacodynamic model of tolerance: application to nicotine. , 1988, The Journal of pharmacology and experimental therapeutics.

[7]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[8]  W J Jusko,et al.  Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. , 1998, Journal of pharmaceutical sciences.

[9]  B. Efron,et al.  Compliance as an Explanatory Variable in Clinical Trials , 1991 .

[10]  John Anthony Bauer,et al.  Application of Pharmacodynamic Modeling for Designing Time-Variant Dosing Regimens to Overcome Nitroglycerin Tolerance in Experimental Heart Failure , 1997, Pharmaceutical Research.

[11]  G. Levy,et al.  Apparent Potentiating Effect of a Second Dose of Drug , 1965, Nature.

[12]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[13]  R. Furchgott,et al.  The pharmacology of vascular smooth muscle. , 1955, Pharmacological reviews.

[14]  M A Nowak,et al.  Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. , 1997, Journal of theoretical biology.

[15]  R C Boston,et al.  Conversational SAAM--an interactive program for kinetic analysis of biological systems. , 1981, Computer programs in biomedicine.

[16]  G. Levy,et al.  Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin , 1969, Clinical pharmacology and therapeutics.

[17]  J. Mandema,et al.  Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. , 1995, The Journal of pharmacology and experimental therapeutics.

[18]  G Levy,et al.  Theoretical relationship between dose, elimination rate, and duration of pharmacologic effect of drugs. , 1965, Journal of Pharmacy and Science.

[19]  S. M. Kupchan,et al.  Tumor Inhibitors III. Monocrotaline, the Active Principle of Crotalaria spectabilis , 1964 .

[20]  F. Frey,et al.  Pharmacokinetics and pharmacodynamics of three different prednisolone prodrugs: effect on circulating lymphocyte subsets and function. , 1984, Journal of immunology.

[21]  David B. Dunson,et al.  Bayesian Data Analysis , 2010 .

[22]  T. Theofanous,et al.  Multiple-dose kinetics of oral anticoagulants: methods of analysis and optimized dosing. , 1973, Journal of pharmaceutical sciences.

[23]  M Danhof,et al.  Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. , 1997, The Journal of pharmacology and experimental therapeutics.

[24]  John Ferguson,et al.  The Use of Chemical Potentials as Indices of Toxicity , 1939 .

[25]  L B Sheiner,et al.  Relationship between the pharmacokinetics and pharmacodynamics of procainamide , 1976, Clinical pharmacology and therapeutics.

[26]  W J Jusko,et al.  Pharmacodynamic modeling of time‐dependent transduction systems , 2001, Clinical pharmacology and therapeutics.

[27]  E. Ekblad,et al.  A model eliciting transient responses. , 1984, The American journal of physiology.

[28]  G. Segre,et al.  Kinetics of interaction between drugs and biological systems. , 1968, Il Farmaco; edizione scientifica.

[29]  M A Nowak,et al.  Virus dynamics and drug therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[30]  D Verotta,et al.  Concepts, properties, and applications of linear systems to describe distribution, identify input, and control endogenous substances and drugs in biological systems. , 1996, Critical reviews in biomedical engineering.

[31]  G Levy,et al.  Kinetics of pharmacologic effects , 1966, Clinical pharmacology and therapeutics.

[32]  J. Black,et al.  Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[33]  Lewis B. Sheiner,et al.  A general conceptual model for non-steady state pharmacokinetic/Pharmacodynamic data , 2006, Journal of Pharmacokinetics and Biopharmaceutics.

[34]  W J Jusko,et al.  Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. , 1971, Journal of pharmaceutical sciences.

[35]  D. Verotta,et al.  A general solution for nonparametric control of a linear system using computer-controlled infusion pumps , 1999, IEEE Transactions on Biomedical Engineering.

[36]  William J. Jusko,et al.  A pharmacodynamic model for cell-cycle-specific chemotherapeutic agents , 1973, Journal of Pharmacokinetics and Biopharmaceutics.

[37]  L B Sheiner,et al.  Population pharmacokinetics/dynamics. , 1992, Annual review of pharmacology and toxicology.

[38]  Richard P. Lewis,et al.  Pharmacokinetics of digoxin: Relationship between response intensity and predicted compartmental drug levels in man , 1979, Journal of Pharmacokinetics and Biopharmaceutics.

[39]  W J Jusko,et al.  Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity , 1991, Clinical pharmacology and therapeutics.

[40]  R J Tallarida Receptor theories and quantitative effect versus dose-concentration relationship. , 1984, Drug metabolism reviews.

[41]  J J DiStefano,et al.  Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations. , 1984, The American journal of physiology.

[42]  William J Jusko,et al.  Diversity of mechanism-based pharmacodynamic models. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[43]  M W Fischman,et al.  Kinetics of cocaine distribution, elimination, and chronotropic effects , 1985, Clinical pharmacology and therapeutics.

[44]  R Byck,et al.  Kinetics of drug effect by distributed lags analysis: An application to cocaine , 1982, Clinical pharmacology and therapeutics.

[45]  J. L. Steimer,et al.  Variability in drug therapy : description, estimation, and control : a Sandoz workshop , 1985 .

[46]  W. Jusko,et al.  Gender‐based effects on methylprednisolone pharmacokinetics and pharmacodynamics , 1993, Clinical pharmacology and therapeutics.

[47]  L B Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models , 1986, Clinical pharmacology and therapeutics.

[48]  Aaron Tucker,et al.  A Bibliography. , 1902, British medical journal.

[49]  William J. Jusko,et al.  Second generation model for prednisolone pharmacodynamics in the rat , 1989, Journal of Pharmacokinetics and Biopharmaceutics.

[50]  L B Sheiner,et al.  Kinetics of pharmacologic response. , 1982, Pharmacology & therapeutics.

[51]  Davide Verotta,et al.  Models and estimation methods for clinical HIV-1 data , 2005 .

[52]  W J Jusko,et al.  Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects , 1989, Clinical pharmacology and therapeutics.

[53]  Hulin Wu,et al.  A Comparison Study of Models and Fitting Procedures for Biphasic Viral Dynamics in HIV‐1 Infected Patients Treated with Antiviral Therapies , 2000, Biometrics.

[54]  D Verotta,et al.  Chronopharmacokinetics of nicotine , 1996, Clinical pharmacology and therapeutics.

[55]  G Levy,et al.  Pharmacologic target‐mediated drug disposition , 1994, Clinical pharmacology and therapeutics.

[56]  J J DiStefano,et al.  Multiexponential, multicompartmental, and noncompartmental modeling. I. Methodological limitations and physiological interpretations. , 1984, The American journal of physiology.

[57]  L B Sheiner,et al.  Semiparametric models for antagonistic drug interactions. , 1994, Journal of applied physiology.

[58]  A S Perelson,et al.  Modeling plasma virus concentration during primary HIV infection. , 2000, Journal of theoretical biology.

[59]  M Danhof,et al.  Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam. , 1998, The Journal of pharmacology and experimental therapeutics.

[60]  M Danhof,et al.  A system approach to pharmacodynamics. III: An algorithm and computer program, COLAPS, for pharmacodynamic modeling. , 1991, Journal of pharmaceutical sciences.

[61]  G Levy,et al.  Multicompartment pharmacokinetic models and pharmacologic effects. , 1969, Journal of pharmaceutical sciences.

[62]  L B Sheiner,et al.  Simultaneous Modeling of Pharmacokinetics and Pharmacodynamics with a Nonparametric Pharmacodynamic Model , 1984, Clinical pharmacology and therapeutics.

[63]  L. Sheiner,et al.  Modelling of individual pharmacokinetics for computer-aided drug dosage. , 1972, Computers and biomedical research, an international journal.

[64]  L B Sheiner,et al.  Computer-aided long-term anticoagulation therapy. , 1969, Computers and biomedical research, an international journal.

[65]  T. Schnider,et al.  Expanding clinical applications of population pharmacodynamic modelling. , 1998, British journal of clinical pharmacology.

[66]  G Levy,et al.  Mechanism‐based pharmacodynamic modeling , 1994, Clinical pharmacology and therapeutics.

[67]  N H Holford,et al.  Concepts and usefulness of pharmacokinetic‐pharmacodynamic modelling , 1990, Fundamental & clinical pharmacology.

[68]  Lewis B. Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: an improved algorithm , 1987, Comput. Appl. Biosci..

[69]  James C. Scott,et al.  Testing computer-controlled infusion pumps by simulation. , 1988, Anesthesiology.

[70]  Berend Oosterhuis,et al.  Pharmacokinetic‐pharmacodynamic modeling of terbutaline bronchodilation in asthma , 1986, Clinical pharmacology and therapeutics.

[71]  Davide Verotta,et al.  An inequality-constrained least-squares deconvolution method , 1989, Journal of Pharmacokinetics and Biopharmaceutics.

[72]  H Wu,et al.  Population HIV‐1 Dynamics In Vivo: Applicable Models and Inferential Tools for Virological Data from AIDS Clinical Trials , 1999, Biometrics.

[73]  Varun Garg,et al.  Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[74]  R. Evans,et al.  The steroid and thyroid hormone receptor superfamily. , 1988, Science.

[75]  W J Jusko,et al.  Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. , 1998, Journal of pharmaceutical sciences.

[76]  William J. Jusko,et al.  Receptor-mediated pharmacodynamics of prednisolone in the rat , 1986, Journal of Pharmacokinetics and Biopharmaceutics.

[77]  L. Paalzow,et al.  Relation between morphine pharmacokinetics and analgesia , 1978, Journal of Pharmacokinetics and Biopharmaceutics.

[78]  L B Sheiner,et al.  Modeling a bivariate control system: LH and testosterone response to the GnRH antagonist antide. , 1996, The American journal of physiology.

[79]  E. J. Ariëns Molecular pharmacolōgy : the mode of action of biologically active compounds , 1964 .

[80]  Vito Volterra,et al.  Theory of Functionals and of Integral and Integro-Differential Equations , 2005 .

[81]  Daniel E. Salazar,et al.  Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics , 1991, Journal of Pharmacokinetics and Biopharmaceutics.

[82]  B. O’Malley,et al.  Mechanisms of action of steroid hormones. , 1971, The New England journal of medicine.

[83]  V. Marmarelis Identification of nonlinear biological systems using laguerre expansions of kernels , 1993, Annals of Biomedical Engineering.

[84]  J. Wagner,et al.  Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. , 1968, Journal of theoretical biology.

[85]  A S Perelson,et al.  Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads. , 1998, Journal of theoretical biology.

[86]  M A Nowak,et al.  Coexistence and competition in HIV infections. , 1992, Journal of theoretical biology.

[87]  M A Nowak,et al.  Mathematical biology of HIV infections: antigenic variation and diversity threshold. , 1991, Mathematical biosciences.

[88]  Davide Verotta,et al.  Volterra Series in Pharmacokinetics and Pharmacodynamics , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[89]  Lewis B. Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine , 1979 .

[90]  Timothy J. O'Leary,et al.  Predicting oral anticoagulant response using a pharmacodynamic model , 2006, Annals of Biomedical Engineering.

[91]  L. Paalzow,et al.  Acute tolerance to furosemide diuresis in humans. Pharmacokinetic-pharmacodynamic modeling. , 1985, The Journal of pharmacology and experimental therapeutics.

[92]  R M May Nonlinearities and Complex Behavior in Simple Ecological and Epidemiological Models a , 1987, Annals of the New York Academy of Sciences.

[93]  A Sibbald,et al.  A pharmacodynamic model for pancuronium. , 1978, British journal of anaesthesia.

[94]  Davide Verotta,et al.  Non-linear dynamics models characterizing long-term virological data from AIDS clinical trials. , 2002, Mathematical biosciences.

[95]  T J O'Leary,et al.  Evaluation of a computer‐assisted method for individualized anticoagulation: Retrospective and prospective studies with a pharmacodynamic model , 1982, Clinical pharmacology and therapeutics.

[96]  M Danhof,et al.  Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam. , 1999, The Journal of pharmacology and experimental therapeutics.

[97]  Carl de Boor,et al.  A Practical Guide to Splines , 1978, Applied Mathematical Sciences.

[98]  Lewis B. Sheiner,et al.  Semiparametric analysis of non-steady-state pharmacodynamic data , 2005, Journal of Pharmacokinetics and Biopharmaceutics.

[99]  L B Sheiner,et al.  Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. , 1982, Journal of pharmaceutical sciences.

[100]  Yangxin Huang,et al.  Mechanistic PK/PD Modeling of Antiretroviral Therapies in AIDS Clinical Trials , 2004 .

[101]  Peter Veng-Pedersen,et al.  Estimation of amobarbital plasma-effect site equilibration kinetics. Relevance of polyexponential conductance functions , 1991, Journal of Pharmacokinetics and Biopharmaceutics.

[102]  P H van der Graaf,et al.  A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[103]  Wojciech Krzyzanski,et al.  Assessment of Drug Interactions Relevant to Pharmacodynamic Indirect Response Models , 2004, Journal of Pharmacokinetics and Pharmacodynamics.

[104]  J Urquhart,et al.  Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens. , 1998, Statistics in medicine.

[105]  L B Sheiner,et al.  Pharmacokinetic‐pharmacodynamic modeling of caffeine: Tolerance to pressor effects , 1993, Clinical pharmacology and therapeutics.

[106]  G. Levy,et al.  RELATIONSHIP BETWEEN ELIMINATION RATE OF DRUGS AND RATE OF DECLINE OF THEIR PHARMACOLOGIC EFFECTS. , 1964, Journal of pharmaceutical sciences.

[107]  C G Brook,et al.  The relationship between endogenous testosterone and gonadotrophin secretion , 1993, Clinical Endocrinology.